Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2023 · 10-Q
Revenue—
Net Income-$539.60K-$539.60KN/M vs Q1 2022 EPS Diluted$0.00$0.00— vs Q1 2022 Operating Income-$629,724N/M Operating Cash Flow-$757,283N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end